27.02.2012 07:20 Uhr, Quelle: Wallstreet online

European Commission approves new label for Novartis drug Glivec® extending adjuvant therapy to three years for certain GIST patients

Novartis International AG / European Commission approves new label for Novartis drug Glivec® extending adjuvant therapy to three years for certain GIST patients . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible …

Weiterlesen bei Wallstreet online